Genprex (GNPX) Retained Earnings (2016 - 2026)
Genprex (GNPX) posted quarterly Retained Earnings of $192.4 million for Q1 2026, up 18.33% year-over-year from $162.6 million in Q1 2025, and up 7.5% quarter-over-quarter from $179.0 million in Q4 2025.
Genprex (GNPX) Retained Earnings (2016 - 2026) Analysis & Trends
Genprex's Retained Earnings history runs 11 years deep, the most recent figure standing at $192.4 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 18.33% year-over-year to $192.4 million; the TTM figure through Mar 2026 stood at $192.4 million (up 18.33% YoY), while the FY2025 annual figure was $179.0 million, up 14.43% from the prior year.
- Retained Earnings for Q1 2026 stood at $192.4 million, up from $179.0 million in the prior quarter.
- The five-year high for Retained Earnings was $192.4 million in Q1 2026, with the low at -$163.4 million in Q2 2025.
- The 5-year median for Retained Earnings is $141.1 million (2023), against an average of $63.8 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 49243.02% in 2024, then sank 208.6% in 2025.
- Genprex's Retained Earnings stood at -$102.8 million in 2022, then surged by 237.22% to $141.1 million in 2023, then increased by 10.85% to $156.4 million in 2024, then rose by 14.43% to $179.0 million in 2025, then grew by 7.5% to $192.4 million in 2026.
- Business Quant data shows GNPX's Retained Earnings at $192.4 million in Q1 2026, $179.0 million in Q4 2025, and $168.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 4.38 Bn |
| 10 | Genprex | 1.91 Mn | -13.25 Mn | - | 194.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.41 Mn |
| Dec 31, 2025 | 178.99 Mn |
| Sep 30, 2025 | 168.00 Mn |
| Jun 30, 2025 | -163.44 Mn |
| Mar 31, 2025 | 162.61 Mn |
| Dec 31, 2024 | 156.42 Mn |
| Sep 30, 2024 | 152.13 Mn |
| Jun 30, 2024 | 150.50 Mn |
| Mar 31, 2024 | 148.41 Mn |
| Dec 31, 2023 | 141.10 Mn |
| Sep 30, 2023 | -127.76 Mn |
| Jun 30, 2023 | -120.01 Mn |
| Mar 31, 2023 | -302,000.00 |
| Dec 31, 2022 | -102.83 Mn |
| Sep 30, 2022 | -96.30 Mn |
| Jun 30, 2022 | 122.53 Mn |
| Mar 31, 2022 | 121.37 Mn |
| Dec 31, 2021 | -79.09 Mn |
| Sep 30, 2021 | -72.34 Mn |
| Jun 30, 2021 | 116.53 Mn |